Last $6.92 USD
Change Today +0.02 / 0.29%
Volume 2.2K
CORI On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

corium international inc (CORI) Snapshot

Open
$6.86
Previous Close
$6.90
Day High
$6.94
Day Low
$6.82
52 Week High
06/18/14 - $8.49
52 Week Low
11/17/14 - $4.30
Market Cap
125.1M
Average Volume 10 Days
3.9K
EPS TTM
$-0.68
Shares Outstanding
18.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORIUM INTERNATIONAL INC (CORI)

Related News

No related news articles were found.

corium international inc (CORI) Related Businessweek News

No Related Businessweek News Found

corium international inc (CORI) Details

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; Crest Whitestrips, which are a series of four products under the Advanced Vivid, Professional Effects, One Hour Express, and Flex-Fit brands for oral care. The company’s products under pipeline comprise AG200-15, a combination hormonal contraceptive patch, which delivers ethinyl estradiol and levonorgestrel hormones has completed a Phase III clinical trial; MicroCor hPTH(1-34), a transdermal system that has completed a Phase I clinical trial for the treatment of severe osteoporosis; and Corplex Tamsulosin that has completed a Phase I clinical trial for the treatment of benign prostatic hyperplasia. In addition, it is developing a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness; a generic transdermal product for the treatment of a urologic condition, as well as Donepezil and Memantine transdermal patches for the treatment of Alzheimer's disease; and Ropinerole and Pramipexole therapies for the treatment of Parkinson's disease. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Par Pharmaceutical, Inc.; Agile Therapeutics, Inc.; and others. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

244 Employees
Last Reported Date: 12/15/14
Founded in 1995

corium international inc (CORI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $582.3K
Chief Financial Officer
Total Annual Compensation: $467.3K
Chief Technology Officer and Vice President o...
Total Annual Compensation: $392.2K
Compensation as of Fiscal Year 2014.

corium international inc (CORI) Key Developments

Corium International, Inc. Announces Unaudited Financial Results for the First Quarter Ended December 31, 2014

Corium International, Inc. announced unaudited financial results for the first quarter ended December 31, 2014. The company reported total revenues in the first quarter of fiscal 2015 of $9.8 million, compared with $10.5 million in the first quarter of fiscal 2014. The reduction in total revenues primarily reflects anticipated declines in product revenues from Clonidine TDS (marketed by Teva Pharmaceuticals) and Fentanyl TDS (marketed by Par Pharmaceutical), partially offset by an increase in sales of Crest Whitestrips to Procter & Gamble as well as an increase in contract research and development revenues from co-development programs and partner-funded programs. The company reported a net loss for the first quarter of fiscal 2015 of $6.8 million, or $0.37 per share on a fully-diluted basis, compared with a net loss of $2.1 million, or $0.94 per share on a fully-diluted basis, in the first quarter of fiscal 2014. The loss per share in the first quarter of fiscal 2014 was impacted by the use of a significantly smaller number of average shares outstanding prior to the IPO, and does not reflect the earnings or losses per share that will occur with Corium's post-IPO capital structure. Loss from operations was $5.090 million against $1.062 million a year ago. Loss before income taxes was $6.757 million against $2.098 million a year ago.

Corium International, Inc. to Report Q1, 2015 Results on Feb 10, 2015

Corium International, Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on Feb 10, 2015

Corium International, Inc., Q1 2015 Earnings Call, Feb 10, 2015

Corium International, Inc., Q1 2015 Earnings Call, Feb 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORI:US $6.92 USD +0.02

CORI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $168.65 USD -0.96
Actavis plc $291.36 USD +1.58
FUJIFILM Holdings Corp ¥4,123 JPY -1.00
Mylan Inc/PA $57.33 USD +0.08
Zogenix Inc $1.68 USD +0.03
View Industry Companies
 

Industry Analysis

CORI

Industry Average

Valuation CORI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 20.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORIUM INTERNATIONAL INC, please visit www.coriumgroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.